Rapid Micro Biosystems (RPID) Small-Cap Virtual Conference summary

Business Overview and Growth Strategy

• Projected 2025 revenue of $34 million with 20% annual growth, driven by a recurring revenue model from consumables and services, and $18 million in recurring revenue.

• Over 200 systems placed globally, with 169 validated systems and significant market penetration potential as the total addressable market is estimated at 8,000–10,000 systems.

• 75% of the top 20 global pharma companies are customers, with a strong presence in advanced modalities like biologics and cell/gene therapy.

• Land-and-expand strategy targets initial site adoption, followed by expansion within and across customer networks and geographies, driving enterprise deployments and new product launches.

• Adjacent market opportunities in personal care, cosmetics, food/beverage, and medical devices are being explored, leveraging a partnership with Merck MilliporeSigma.

Technology, Product Innovation, and Value Proposition

• Growth Direct platform is the only fully automated, high-throughput, and secure microbial quality control solution, replacing slow, manual Petri dish methods.

• System integrates with customer data management, enabling paperless, secure, and efficient workflows, and supports global regulatory compliance.

• Delivers faster, more accurate results, reducing turnaround from weeks to days and time to results by 50% or more, while eliminating human error and reducing risk of costly recalls.

• Automates key tests: environmental monitoring, water, bioburden, and sterility, supporting high-volume daily operations and advanced therapies.

• Positioned as the new standard in microbial quality control, transforming a critical part of pharma manufacturing with a robust patent portfolio.

Financial Outlook and Margin Expansion

• Recurring revenue exceeds 50% of total, underpinning financial stability and growth.

• Gross margin inflecting upward: 15% in Q2, guiding to 20% for the year, targeting 50%+ by 2026 exit and 2028 through cost reduction and volume leverage.

• Cash position at end of Q2 was $20 million, with additional capital available via debt and potential warrant exercises.

• Disciplined capital allocation and ongoing efforts to strengthen the balance sheet support the goal of cash flow break-even by end of 2028 and maximize shareholder value.

• Consistent 20%+ revenue CAGR projected, with 2026 guidance of $37–$41 million.